Current Value
$2.311 Year Return
Current Value
$2.311 Year Return
Finnhub
Seoul - ABL Bio , a company specializing in bispecific antibodies, announced its partner I-Mab published clinical data on ABL111/Givastomig, a bispecific antibody targeting Claudin18.2 and 4-1BB, in...
Yahoo
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announc
Finnhub
Transforming Potential into Reality Mab Biopharma July 2025 ...
Yahoo
Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Can
Yahoo
Over the last 7 days, the U.S. market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. In light of these conditions, identifying stocks that offer both value and growth potential becomes crucial for investors seeking opportunities in smaller companies. Penny stocks, although an outdated term, continue to represent a segment of the market where smaller or newer companies can provide promising investment prospects when backed by strong...
Yahoo
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated results to be presented at ESMO GI on July 2nd Company to host investor event on July 8th ROCKVILLE, Md., June 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BULL | 37.36% | $6.47B | +25.76% | 0.00% |
FERG | 29.16% | $43.66B | +16.54% | 1.11% |
CTRN | 28.56% | $274.86M | +71.98% | 0.00% |
TPST | 26.76% | $29.14M | -74.01% | 0.00% |
ANGO | 26.37% | $381.30M | +65.32% | 0.00% |
BW | 25.95% | $99.39M | -43.26% | 0.00% |
HOFT | 24.76% | $122.80M | -15.15% | 8.12% |
CATX | 24.67% | $251.63M | -68.47% | 0.00% |
ALT | 24.03% | $397.42M | -25.76% | 0.00% |
AQN | 23.58% | $4.51B | -5.00% | 4.54% |
HXL | 23.24% | $4.63B | -11.12% | 1.11% |
CHMI | 23.01% | $90.46M | -24.32% | 21.74% |
VVV | 22.37% | $4.94B | -9.49% | 0.00% |
STX | 22.28% | $32.24B | +49.89% | 1.89% |
CMBT | 22.23% | $1.83B | -43.70% | 2.84% |
GEF | 22.21% | $4.05B | +21.85% | 3.10% |
MP | 22.01% | $5.29B | +128.60% | 0.00% |
CNM | 21.64% | $11.73B | +26.49% | 0.00% |
LE | 21.63% | $352.87M | -14.03% | 0.00% |
CLAR | 21.60% | $140.55M | -42.45% | 2.73% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SXC | -0.01% | $747.47M | -13.69% | 5.48% |
NNE | 0.01% | $1.37B | +39.32% | 0.00% |
MCW | 0.01% | $2.10B | -5.40% | 0.00% |
CARV | 0.02% | $8.88M | +26.23% | 0.00% |
PBH | -0.05% | $3.96B | +19.10% | 0.00% |
CBZ | 0.05% | $3.94B | -2.79% | 0.00% |
CPB | 0.06% | $9.52B | -29.04% | 4.82% |
TOST | 0.07% | $24.61B | +68.08% | 0.00% |
OSCR | -0.07% | $4.23B | -2.64% | 0.00% |
FNV | -0.07% | $31.68B | +34.04% | 0.90% |
FTS | 0.08% | $23.62B | +20.13% | 3.70% |
PODD | -0.11% | $21.23B | +53.32% | 0.00% |
CLMT | -0.11% | $1.42B | +2.13% | 0.00% |
HTZ | -0.13% | $1.02B | +104.86% | 0.00% |
PLMR | -0.13% | $3.84B | +74.61% | 0.00% |
MMS | 0.13% | $4.08B | -15.03% | 1.66% |
COST | -0.14% | $435.65B | +13.88% | 0.49% |
CRON | -0.15% | $770.84M | -13.79% | 0.00% |
BG | -0.17% | $10.94B | -25.60% | 3.39% |
KO | 0.17% | $305.22B | +11.97% | 2.81% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STTK | -14.12% | $40.57M | -77.11% | 0.00% |
K | -11.79% | $27.76B | +41.17% | 2.85% |
CVM | -11.43% | $12.94M | -92.36% | 0.00% |
CME | -10.95% | $99.39B | +40.68% | 3.86% |
UONEK | -10.78% | $28.99M | -56.51% | 0.00% |
LRN | -10.48% | $5.99B | +100.06% | 0.00% |
KVUE | -10.31% | $40.13B | +14.15% | 3.92% |
IRWD | -10.25% | $119.70M | -87.89% | 0.00% |
BARK | -9.36% | $158.83M | -44.50% | 0.00% |
CI | -8.81% | $85.59B | -1.55% | 1.81% |
EIX | -8.74% | $20.22B | -26.82% | 6.10% |
UVV | -8.45% | $1.44B | +22.56% | 5.57% |
CNK | -8.44% | $3.47B | +41.29% | 0.53% |
NG | -8.43% | $1.82B | +29.48% | 0.00% |
MKTX | -8.29% | $8.22B | +9.03% | 1.38% |
CNX | -8.01% | $4.69B | +30.63% | 0.00% |
PCG | -7.94% | $30.75B | -18.76% | 0.61% |
COR | -7.84% | $56.44B | +30.86% | 0.74% |
FLYW | -7.77% | $1.44B | -25.92% | 0.00% |
MO | -7.74% | $99.67B | +28.77% | 6.90% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EWH | 24.12% | $641.99M | 0.5% |
EMGF | 22.71% | $913.36M | 0.26% |
FLRT | 22.61% | $512.16M | 0.6% |
EYLD | 22.35% | $525.37M | 0.63% |
PFLD | 21.61% | $494.50M | 0.45% |
IWMY | 21.48% | $119.32M | 1.02% |
ESGE | 21.06% | $5.01B | 0.26% |
GEM | 20.87% | $1.02B | 0.45% |
PREF | 20.85% | $1.23B | 0.55% |
AIA | 20.83% | $750.32M | 0.5% |
EMXF | 20.64% | $102.08M | 0.17% |
AVEM | 20.41% | $10.77B | 0.33% |
DEHP | 20.27% | $264.22M | 0.41% |
FNDE | 20.25% | $6.99B | 0.39% |
JPEM | 20.15% | $337.92M | 0.44% |
AAXJ | 20.11% | $2.70B | 0.72% |
QQQY | 20.08% | $166.08M | 1% |
XSOE | 19.94% | $1.87B | 0.32% |
DFEM | 19.90% | $5.58B | 0.39% |
PXH | 19.86% | $1.49B | 0.47% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BGRN | -<0.01% | $404.12M | 0.2% |
VNLA | 0.01% | $2.62B | 0.23% |
STPZ | 0.01% | $450.47M | 0.2% |
BIV | -0.01% | $23.39B | 0.03% |
MBB | -0.03% | $39.33B | 0.04% |
IBTG | -0.04% | $1.92B | 0.07% |
FXG | 0.06% | $294.43M | 0.63% |
IBTM | -0.06% | $316.49M | 0.07% |
FTSM | -0.07% | $6.37B | 0.45% |
GNMA | 0.09% | $368.65M | 0.1% |
NUAG | 0.13% | $58.85M | 0.19% |
SPAB | 0.15% | $8.82B | 0.03% |
IBTH | -0.16% | $1.62B | 0.07% |
ILTB | 0.17% | $595.04M | 0.06% |
CLIP | -0.21% | $1.51B | 0.07% |
UBND | 0.22% | $1.02B | 0.4% |
SCHP | 0.23% | $12.99B | 0.03% |
TIPX | -0.24% | $1.74B | 0.15% |
REZ | -0.24% | $790.30M | 0.48% |
BND | -0.26% | $131.38B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GBIL | -19.73% | $6.37B | 0.12% |
VIXY | -19.36% | $164.54M | 0.85% |
TAIL | -16.78% | $99.63M | 0.59% |
FXY | -13.67% | $816.38M | 0.4% |
IBD | -13.28% | $385.27M | 0.43% |
TPMN | -12.29% | $30.70M | 0.65% |
BTAL | -12.23% | $296.22M | 1.43% |
IBTF | -11.33% | $1.99B | 0.07% |
USFR | -8.58% | $18.56B | 0.15% |
TBLL | -7.90% | $2.13B | 0.08% |
XONE | -7.73% | $625.28M | 0.03% |
ICSH | -6.89% | $6.02B | 0.08% |
OWNS | -6.65% | $129.31M | 0.3% |
AGGH | -6.52% | $324.95M | 0.29% |
XBIL | -6.15% | $783.90M | 0.15% |
SGOV | -5.70% | $49.21B | 0.09% |
GLDM | -5.36% | $15.74B | 0.1% |
BWX | -5.33% | $1.53B | 0.35% |
AAAU | -5.25% | $1.54B | 0.18% |
BAR | -5.05% | $1.11B | 0.1749% |